{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:33:20Z","timestamp":1773293600427,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"am","delay-in-days":291,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jsat.2022.108852","type":"journal-article","created":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T00:49:05Z","timestamp":1659228545000},"page":"108852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder"],"prefix":"10.1016","volume":"142","author":[{"given":"Audun J.","family":"Lier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Seval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent","family":"Vander Wyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Di Paola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra A.","family":"Springer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2022.108852_bb0005","author":"Ahmad"},{"issue":"12","key":"10.1016\/j.jsat.2022.108852_bb0010","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1093\/cid\/ciz693","article-title":"Low hepatitis C reinfection following direct-acting antiviral therapy among people who inject drugs on opioid agonist therapy","volume":"70","author":"Akiyama","year":"2020","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1016\/j.jsat.2022.108852_bb0015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMsa064115","article-title":"Release from prison\u2013A high risk of death for former inmates","volume":"356","author":"Binswanger","year":"2007","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.jsat.2022.108852_bb0020","article-title":"Reduced sexual risk behaviors among persons with HIV after release from the criminal justice system","volume":"6","author":"Biondi","year":"2019","journal-title":"Open forumInfectious Diseases"},{"key":"10.1016\/j.jsat.2022.108852_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2021.100704","article-title":"Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder","volume":"21","author":"Biondi","year":"2021","journal-title":"Contemporary Clinical Trials Communications"},{"issue":"1","key":"10.1016\/j.jsat.2022.108852_bb0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13722-022-00299-1","article-title":"Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community","volume":"17","author":"Biondi","year":"2022","journal-title":"Addiction Science & Clinical Practice"},{"issue":"11","key":"10.1016\/j.jsat.2022.108852_bb0035","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0005-7967(02)00039-6","article-title":"Clinically useful assessments: Substance use and comorbid psychiatric disorders","volume":"40","author":"Carey","year":"2002","journal-title":"Behaviour Research and Therapy"},{"issue":"1","key":"10.1016\/j.jsat.2022.108852_bb0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13722-019-0136-6","article-title":"Illicit substance use after release from prison among formerly incarcerated primary care patients: a cross sectional study","volume":"14","author":"Chamberlain","year":"2019","journal-title":"Addiction Science and Clinical Practice"},{"issue":"4","key":"10.1016\/j.jsat.2022.108852_bb0045","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","article-title":"The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis","volume":"34","author":"Ciccarone","year":"2021","journal-title":"Current Opinion in Psychiatry"},{"issue":"1","key":"10.1016\/j.jsat.2022.108852_bb0050","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jsat.2009.06.004","article-title":"Measurement of self-reported HIV risk behaviors in injection drug users: Comparison of standard versus timeline follow-back administration procedures","volume":"38","author":"Copersino","year":"2010","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"10.1016\/j.jsat.2022.108852_bb0055","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cct.2014.09.002","article-title":"Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community","volume":"39","author":"Di Paola","year":"2014","journal-title":"Contemporary Clinical Trials"},{"issue":"10049","key":"10.1016\/j.jsat.2022.108852_bb0060","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0140-6736(16)30466-4","article-title":"Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees","volume":"388","author":"Dolan","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jsat.2022.108852_bb0065","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.drugalcdep.2014.03.006","article-title":"The impact of buprenorphine\/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients","volume":"139","author":"Edelman","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.jsat.2022.108852_bb0070","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jama.2018.21167","article-title":"HIV viral load and transmissibility of HIV infection: Undetectable equals untransmittable","volume":"321","author":"Eisinger","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jsat.2022.108852_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108076","article-title":"A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder","volume":"117","author":"Farabee","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"10.1016\/j.jsat.2022.108852_bb0080","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1360-0443.2006.01316.x","article-title":"Substance abuse and dependence in prisoners: a systematic review [Research Support, Non-U.S. Gov't Review]","volume":"101","author":"Fazel","year":"2006","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.jsat.2022.108852_bb0085","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/01.qai.0000192000.15777.5c","article-title":"Clinician-delivered intervention during routine clinical care reduces unprotected sexual behavior among HIV-infected patients","volume":"41","author":"Fisher","year":"2006","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"5","key":"10.1016\/j.jsat.2022.108852_bb0090","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/add.14878","article-title":"The rise in non-fatal and fatal overdoses involving stimulants with and without opioids in the United States","volume":"115","author":"Hoots","year":"2020","journal-title":"Addiction"},{"issue":"17","key":"10.1016\/j.jsat.2022.108852_bb0095","doi-asserted-by":"crossref","first-page":"388","DOI":"10.15585\/mmwr.mm6817a3","article-title":"Drug overdose deaths involving cocaine and psychostimulants with abuse potential\u2014United States, 2003\u20132017","volume":"68","author":"Kariisa","year":"2019","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.jsat.2022.108852_bb0100","article-title":"The impact of methadone maintenance treatment on HIV risk behaviors among high-risk injection drug users: A systematic review","volume":"2","author":"Karki","year":"2016","journal-title":"Evidence-based Medicine & Public Health"},{"issue":"9776","key":"10.1016\/j.jsat.2022.108852_bb0105","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.jsat.2022.108852_bb0110","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders","volume":"374","author":"Lee","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"10118","key":"10.1016\/j.jsat.2022.108852_bb0115","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"Supplement_5","key":"10.1016\/j.jsat.2022.108852_bb0120","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1093\/infdis\/jiaa432","article-title":"Infectious diseases and injection drug use: Public health burden and response","volume":"222","author":"Levitt","year":"2020","journal-title":"The Journal of Infectious Diseases"},{"issue":"13","key":"10.1016\/j.jsat.2022.108852_bb0125","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJMp1716871","article-title":"Hepatitis C in injection-drug users - A hidden danger of the opioid epidemic","volume":"378","author":"Liang","year":"2018","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.jsat.2022.108852_bb0130","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jsat.2006.04.005","article-title":"HIV risk behaviors during pharmacologic treatment for opioid dependence: A comparison of levomethadyl acetate [corrected] buprenorphine, and methadone","volume":"31","author":"Lott","year":"2006","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"8","key":"10.1016\/j.jsat.2022.108852_bb0135","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1093\/cid\/ciw416","article-title":"Impact of opioid substitution therapy on antiretroviral therapy outcomes: A systematic review and meta-analysis","volume":"63","author":"Low","year":"2016","journal-title":"Clinical Infectious Diseases"},{"issue":"10","key":"10.1016\/j.jsat.2022.108852_bb0140","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/archpsyc.62.10.1157","article-title":"Comparison of pharmacological treatments for opioid-dependent adolescents: A randomized controlled trial","volume":"62","author":"Marsch","year":"2005","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1016\/j.jsat.2022.108852_bb0145","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/QAI.0b013e3181d916db","article-title":"HIV risk behavior in treatment-seeking opioid-dependent youth: Results from a NIDA clinical trials network multisite study","volume":"55","author":"Meade","year":"2010","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"5","key":"10.1016\/j.jsat.2022.108852_bb0150","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamainternmed.2014.601","article-title":"Optimization of human immunodeficiency virus treatment during incarceration: Viral suppression at the prison gate","volume":"174","author":"Meyer","year":"2014","journal-title":"JAMA Internal Medicine"},{"key":"10.1016\/j.jsat.2022.108852_bb0155","author":"NIDA"},{"issue":"7","key":"10.1016\/j.jsat.2022.108852_bb0160","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1016\/S2352-3018(17)30045-0","article-title":"Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996\u20132013: A modelling study","volume":"4","author":"Nosyk","year":"2017","journal-title":"Lancet HIV"},{"issue":"4","key":"10.1016\/j.jsat.2022.108852_bb0165","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3109\/00952999809019608","article-title":"Prevalence of DSM-IV substance abuse and dependence disorders among prison inmates","volume":"24","author":"Peters","year":"1998","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"issue":"13","key":"10.1016\/j.jsat.2022.108852_bb9000","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"7","author":"Royston","year":"2013","journal-title":"BMC Medical Research Methodology"},{"key":"10.1016\/j.jsat.2022.108852_bb0170","author":"SAMHSA"},{"issue":"9631","key":"10.1016\/j.jsat.2022.108852_bb0175","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/S0140-6736(08)60954-X","article-title":"Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: A randomised, double-blind, placebo-controlled trial","volume":"371","author":"Schottenfeld","year":"2008","journal-title":"Lancet"},{"issue":"Suppl. 20","key":"10.1016\/j.jsat.2022.108852_bb0180","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 [Comparative Study Historical Article Research Support, Non-U.S. Gov\u2019t Review]","volume":"59","author":"Sheehan","year":"1998","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.jsat.2022.108852_bb0185","series-title":"Measuring alcohol consumption","first-page":"41","article-title":"Timeline follow-back","author":"Sobell","year":"1992"},{"key":"10.1016\/j.jsat.2022.108852_bb0190","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.drugalcdep.2015.10.023","article-title":"Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system","volume":"157","author":"Springer","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.jsat.2022.108852_bb0195","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s11524-010-9438-4","article-title":"Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: The impact of buprenorphine treatment","volume":"87","author":"Springer","year":"2010","journal-title":"Journal of Urban Health"},{"issue":"1","key":"10.1016\/j.jsat.2022.108852_bb0200","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/QAI.0000000000001634","article-title":"Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: Results of a double-blind, placebo-controlled randomized trial","volume":"78","author":"Springer","year":"2018","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"1","key":"10.1016\/j.jsat.2022.108852_bb0205","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/QAI.0000000000001759","article-title":"Extended-release naltrexone improves viral suppression levels in prisoners with HIV and alcohol use disorders who are transitioning to the community: Results from a double-blind, placebo-controlled trial","volume":"79","author":"Springer","year":"2018","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"12","key":"10.1016\/j.jsat.2022.108852_bb0210","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1086\/421392","article-title":"Effectiveness of antiretroviral therapy among HIV-infected prisoners: Reincarceration and the lack of sustained benefit after release to the community","volume":"38","author":"Springer","year":"2004","journal-title":"Clinical Infectious Diseases"},{"issue":"5","key":"10.1016\/j.jsat.2022.108852_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038335","article-title":"Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners [Research Support, N.I.H., Extramural]","volume":"7","author":"Springer","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jsat.2022.108852_bb0220","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jsat.2007.08.004","article-title":"Buprenorphine\/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors","volume":"35","author":"Sullivan","year":"2008","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"12","key":"10.1016\/j.jsat.2022.108852_bb0225","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: A randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"10.1016\/j.jsat.2022.108852_bb0230","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-156-11-201206050-00419","article-title":"Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel","volume":"156","author":"Thompson","year":"2012","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jsat.2022.108852_bb0235","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jsat.2019.10.005","article-title":"Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine","volume":"109","author":"Tsui","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"10.1016\/j.jsat.2022.108852_bb0240","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/02791072.2014.901587","article-title":"Patterns of abstinence or continued drug use among methadone maintenance patients and their relation to treatment retention","volume":"46","author":"White","year":"2014","journal-title":"Journal of Psychoactive Drugs"},{"issue":"108355","key":"10.1016\/j.jsat.2022.108852_bb0245","article-title":"Extended release injectable naltrexone before vs. after release: A randomized trial of opioid addicted persons who are in prison","volume":"127","author":"Woody","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"17","key":"10.1016\/j.jsat.2022.108852_bb0250","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.2008.574","article-title":"Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial","volume":"300","author":"Woody","year":"2008","journal-title":"JAMA"}],"updated-by":[{"DOI":"10.1016\/j.josat.2023.209074","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000}}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547222001349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547222001349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T15:42:44Z","timestamp":1681314164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547222001349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":51,"alternative-id":["S0740547222001349"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108852","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.josat.2023.209074","asserted-by":"object"}]},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108852","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108852"}}